ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2236

Global Prevalence of Hyperuricemia: A Systematic Review of Population-Based Epidemiological Studies

Emma Smith1 and Lyn March2, 1Department of Rheumatology, Northern Clinical School, Institute of Bone and Joint Research, Kolling Institute, University of Sydney & Department of Rheumatology, Royal North Shore Hospital, St. Leonards, Sydney, Australia, 2Department of Rheumatology, Northern Clinical School, Institute of Bone and Joint Research, Kolling Institute, University of Sydney & Department of Rheumatology, Royal North Shore Hospital, St Leonards, Sydney, Australia

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Epidemiologic methods and hyperuricemia

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 10, 2015

Title: Epidemiology and Public Health Poster III (ACR): Gout and Non-Inflammatory Musculoskeletal Conditions

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Hyperuricemia, or raised serum uric acid (SUA), is the condition closely associated with gout due to the deposition of monosodium urate crystals in peripheral joints and soft tissues. Gout is a chronic musculoskeletal (MSK) disease affecting 1-2% of the world’s population and has been identified as one of the major MSK disorders contributing to the rising MSK burden in the Global Burden of Diseases (GBD), Injuries and Risk Factors 2010 & 2013 Studies. Hyperuricemia has also been reported as an independent risk factor for coronary heart disease, the metabolic syndrome, diabetes, stroke and incident mortality. Broader dissemination of hyperuricemia prevalence data should facilitate improvement of gout and other chronic diseases prevention and management strategies.

The purpose of this study is to systematically review published literature and capture country-specific population-based data on the global prevalence of hyperuricemia.

Methods: Using the following terms: ‘gout or hyperuri*’ combined with the terms: ‘prevalen* or epidemiolo*’, literature searches were performed for the period Jan 1980 to May 2015 on MEDLINE, EMBASE, CINAHL, CAB Abstracts, WHO Library (WHOLIS) and OpenSIGLE. Inclusion and exclusion criteria were set to identify relevant population-based epidemiological studies for the data extraction. Data were extracted into an Excel spreadsheet, and grouped according to the GBD classified 21 world regions.

Results: Published population-based prevalence data of hyperuricemia were reported in 13 of the 21 GBD regions, and a total of 24 countries. Although hyperuricemia was relatively more prevalent in Asia regions, the lowest (Papua New Guinea 1%) and highest (Marshall Islands 85%) reported prevalence were both in Oceania. The widest range of prevalence was observed in East Asia. It was also noted that over two decades, the prevalence of hyperuricemia in High Income Asia Pacific (Japan) increased by 5 fold. Range of the extracted prevalence data reported by various studies are shown in the table below. The data were for both females & males combined unless specified. For the eight regions marked with “No data”, no published population-based epidemiological studies on hyperuricemia were identified during the specified systematic review period.

Prevalence of Hyperuricemia in GBD Regions

GBD Region

Prevalence (%)

Central Asia

 

  • Mongolia

5 (Females) / 18 (Males)

East Asia

 

  • China

6-25

  • Taiwan

10-52

High Income Asia Pacific

 

  • Japan

4 (1980s) / 20-26 (2000s)

  • South Korea

5

South Asia

No data

Southeast Asia

 

  • Indonesia

18

  • Philippines

25

  • Seychelles

25

  • Thailand

9-11

Australasia

 

  • New Zealand

8 (non-Maori) / 17-19 (Maori)

Caribbean

No data

Central Europe

No data

Eastern Europe

 

  • Russia

17

Western Europe

 

  • Italy

9-12

  • Spain

5-11

  • Sweden

10-16

Andean Latin America

No data

Central Latin America

 

  • Mexico

11

Southern Latin America

No data

Tropical Latin America

 

  • Brazil

13

North Africa and Middle East

 

  • Iran

8

  • Saudi Arabia

8

  • Turkey

12

High Income North America

 

  • USA

22 (Females) / 21 (Males)

Oceania

 

  • Marshall Islands

85

  • Papua New Guinea

1

  • Samoa

33

Central Sub-Saharan Africa

No data

East Sub-Saharan Africa

No data

Southern Sub-Saharan Africa

No data

West Sub-Saharan Africa

 

  • Nigeria

17

Conclusion: Elevation of serum uric acid (SUA) is evident throughout all regions of the world, where it has been measured, but considerable regional variation exists. Significant increases are evident in regions that have trend data available. The rising burden of gout together with increasing burden of obesity and ageing globally further emphasises the importance and urgent need for the development of prevention and management strategies for hyperuricemia and gout. Population-based epidemiological research and report on hyperuricemia and gout, particularly in regions of the world with no data, should be encouraged.


Disclosure: E. Smith, None; L. March, None.

To cite this abstract in AMA style:

Smith E, March L. Global Prevalence of Hyperuricemia: A Systematic Review of Population-Based Epidemiological Studies [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/global-prevalence-of-hyperuricemia-a-systematic-review-of-population-based-epidemiological-studies/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/global-prevalence-of-hyperuricemia-a-systematic-review-of-population-based-epidemiological-studies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology